China, the most populous country of the world, is facing increased pressure on healthcare and growing death rates from chronic diseases.
|Pharmaceutical business environment||China’s pharmaceutical market is expected to grow to 64 bn USD in 2015 (ex-manufacturer price level) at a CAGR of 19.4% in the period 2011– 2015 (IMS)|
|Size||Size China is expected to enter 2011 as No. 3 in the global pharma market ranking (IMS)|
|Future development||In 2020, China is expected to be No. 2 in the pharma market.|
|Problems, i.e. political regulation of the market||Market access policies, such as pricing and reimbursement, are the main issues|
|RX and CHC market in China||China’s OTC market size is 9 billion USD and is projected to become 2nd biggest OTC market by 2013 at the latest|